Compare CREG & CANF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CREG | CANF |
|---|---|---|
| Founded | N/A | 1994 |
| Country | China | Israel |
| Employees | N/A | N/A |
| Industry | Power Generation | Biotechnology: Pharmaceutical Preparations |
| Sector | Utilities | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.4M | 4.7M |
| IPO Year | 2019 | 2011 |
| Metric | CREG | CANF |
|---|---|---|
| Price | $0.33 | $3.05 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $9,750.00 |
| AVG Volume (30 Days) | ★ 7.2M | 30.7K |
| Earning Date | 05-14-2026 | 03-26-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $262,509.00 | N/A |
| Revenue This Year | N/A | $2,715,455.50 |
| Revenue Next Year | N/A | $101.06 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.19 | $0.17 |
| 52 Week High | $2.66 | $10.40 |
| Indicator | CREG | CANF |
|---|---|---|
| Relative Strength Index (RSI) | 27.74 | 38.64 |
| Support Level | $0.19 | $2.95 |
| Resistance Level | $1.50 | $4.74 |
| Average True Range (ATR) | 0.08 | 0.17 |
| MACD | 0.02 | 0.00 |
| Stochastic Oscillator | 35.23 | 30.59 |
Smart Powerr Corp is a pioneer in waste energy recycling and a developer of energy efficiency solutions for various energy-intensive industries in China. It uses the Build-Operate-Transfer (BOT) model to provide energy-saving and recovery facilities for multiple energy-intensive industries in China. Its waste energy recycling projects allow customers which use substantial amounts of electricity to recapture previously wasted pressure, heat, and gas from their manufacturing processes to generate electricity. The company offers waste energy recycling systems to companies for use in nonferrous metal plants. It constructs its projects at its customer's facility and the electricity produced is used on-site by the customer.
Can Fite Biopharma Ltd is a clinical-stage biopharmaceutical company. The company focuses on developing orally bioavailable small-molecule drugs targeting the A3 adenosine receptor for treating cancer, inflammatory diseases, liver disorders, and related conditions. It has a pipeline of proprietary drug candidates in Phase II and Phase III clinical development. The company's platform targets the A3 adenosine receptor (A3AR), which is more expressed in inflammatory and cancerous cells than in normal cells. Its pipeline drugs include Namodenoson, Piclidenoson, CF602, and Cannabinoids.